Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00401-011-0891-2 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Expression of MYD88 L265P Mutation in Subtypes of Diffuse Large B-Cell Lymphoma in the Pakistani Population.
Appl Immunohistochem Mol Morphol
January 2025
Department of Histopathology.
Article Synopsis
- The MYD88 L265P mutation, linked to increased cancer cell activity, is prevalent in Waldenstrom macroglobulinemia and non-germinal center diffuse large B-cell lymphoma (DLBCL) but its occurrence in the Pakistani population is not well-documented.
- A study at the Armed Forces Institute of Pathology analyzed 82 DLBCL cases, finding the mutation in 3.6% of germinal center B-cell (GCB) subtype and 22.2% of non-GCB subtype cases.
- The significant association (P = 0.024) suggests that targeting this mutation could improve treatment outcomes for DLBCL patients, especially those with the non-GCB subtype.
Lasalocid A selectively induces the degradation of MYD88 in lymphomas harboring the MYD88 L265P mutation.
Blood
November 2024
Baylor College of Medicine, Houston, Texas, United States.
Article Synopsis
- MYD88 is a key protein involved in immune signaling and is commonly mutated (L265P) in blood cancers, leading to tumor progression.
- Researchers discovered lasalocid-A, a small molecule that selectively kills lymphoma cells with the MYD88 L265P mutation by promoting the degradation of the mutated protein.
- The study showed that lasalocid-A not only effectively works in lab models but also has potential benefits for treating resistant lymphoma types and can enhance the effects of other cancer drugs.
Testicular large B-cell lymphoma is genetically similar to PCNSL and distinct from nodal DLBCL.
Hemasphere
October 2024
Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) Barcelona Spain.
Article Synopsis
- * A study involving 61 TLBCL patients analyzed their genetic characteristics compared to nodal DLBCL and primary CNS large B-cell lymphomas; findings indicated that TLBCL has fewer copy number changes but more somatic mutations than nodal DLBCL.
- * The results highlight a unique genetic profile for TLBCL, with most cases classified as MCD, indicating genetic diversity, suggesting that this lymphoma type warrants targeted treatment strategies due to its distinct biology.
Investigating the frequency of somatic MYD88 L265P mutation in primary ocular adnexal B cell lymphoma.
Mol Biol Rep
September 2024
Department of Molecular Genetics, Aravind Medical Research Foundation, 1, Anna Nagar, Madurai, Tamil Nadu, India.
Background: Ocular adnexal B cell lymphoma is the most common orbital malignancy in adults. Large chromosomal translocations and alterations in cell-signaling pathways were frequently reported in lymphomas. Among the altered pathways, perturbations of NFκB signaling play a significant role in lymphomagenesis.
View Article and Find Full Text PDFSimplified Risk Stratification Model for Patients With Waldenström Macroglobulinemia.
J Clin Oncol
July 2024
Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN.
Article Synopsis
- The study focuses on the prognosis of patients with Waldenström macroglobulinemia (WM) and reassesses traditional prognostic scoring systems in light of new therapies and genetic data.
- Researchers analyzed records of 889 treatment-naïve WM patients to identify clinical predictors influencing overall survival, leading to a new prognostic model based on factors like age and serum levels.
- The newly developed Modified Staging System for WM (MSS-WM) successfully categorizes patients into four distinct risk groups based on their clinical data, demonstrating significant differences in 5-year overall survival rates.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!